Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ribomic, Inc. ( (JP:4591) ) has provided an update.
RIBOMIC, Inc. announced the successful results of their Phase II clinical trial for umedaptanib pegol, an anti-FGF2 aptamer, aimed at treating achondroplasia in pediatric patients. The trial showed improved height growth velocity in patients previously treated with VOXZOGO®. The company plans to monetize this project and seek partners for Phase 3 trials, with a final analysis expected in March 2026.
More about Ribomic, Inc.
RIBOMIC, Inc. is a clinical-stage pharmaceutical company that specializes in aptamer therapeutics, focusing on developing treatments for various medical conditions.
Average Trading Volume: 2,432,441
Technical Sentiment Signal: Sell
Current Market Cap: Yen4.98B
See more data about 4591 stock on TipRanks’ Stock Analysis page.